NLRP3 inflammasome activation in macrophages adjacent to calcified areas creates a pro-osteogenic niche via IL-1β and TNF-α secretion, with pharmacological inhibition of NLRP3 attenuating VC in CKD models (35, 80). This evidence concerns the gene NLRP3 and chronic kidney disease.